Literature DB >> 26372804

ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine.

Gaëtane C Michaud1, Colleen L Channick2, Chad R Marion1, Robert M Tighe3, James A Town4, Andrew M Luks4, Jeremy B Richards5, Sucharita Kher6, Prerna Mota6, Gina Hong7, Natalie E West7, Craig Rackley3, Luke Neilans3, Josanna Rodriguez-Lopez2, Hilary DuBrock2, Cassie C Kennedy8, Diana J Kelm8, Carey C Thomson9.   

Abstract

Keywords:  advanced lung disease; congenital lung disease; lung transplant; obstructive lung disease; pulmonary diagnostic testing

Mesh：

Year:  2015        PMID： 26372804      PMCID： PMC5802516          DOI： 10.1513/AnnalsATS.201504-194CME

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN： 2325-6621


× No keyword cloud information.
  60 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension.

Authors:  Stephen C Mathai; Milo A Puhan; Diana Lam; Robert A Wise
Journal:  Am J Respir Crit Care Med       Date:  2012-06-21       Impact factor: 21.405

Review 3.  Systemic diseases and the lung.

Authors:  Robert Dinwiddie; Samatha Sonnappa
Journal:  Paediatr Respir Rev       Date:  2005-09       Impact factor: 2.726

Review 4.  Extended donor criteria in lung transplantation.

Authors:  Phil Botha
Journal:  Curr Opin Organ Transplant       Date:  2009-04       Impact factor: 2.640

Review 5.  Measurement properties of the incremental shuttle walk test. a systematic review.

Authors:  Verônica F Parreira; Tania Janaudis-Ferreira; Rachel A Evans; Sunita Mathur; Roger S Goldstein; Dina Brooks
Journal:  Chest       Date:  2014-06       Impact factor: 9.410

Review 6.  Obliterative bronchiolitis.

Authors:  Alan F Barker; Anne Bergeron; William N Rom; Marshall I Hertz
Journal:  N Engl J Med       Date:  2014-05-08       Impact factor: 91.245

7.  Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.

Authors:  A E O'Donnell; A F Barker; J S Ilowite; R B Fick
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

Review 8.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

Review 9.  Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review.

Authors:  Gustavo J Rodrigo; Hugo Neffen; José A Castro-Rodriguez
Journal:  Chest       Date:  2010-08-05       Impact factor: 9.410

10.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.